


A marked up version of the amendments pursuant to 37 CFR 1.121 is enclosed.

Entry of these amendments are respectfully requested.

Respectfully submitted,



Irina E. Vainberg
Reg. No. 48,008
Agent for Applicants

DARBY & DARBY P.C.
805 Third Avenue
New York, New York 10022
212-527-7700

202210:00221001

EXPRESS MAIL CERTIFICATE

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT
ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR
DEPOSIT ACCOUNT NO. 04-0100

Date 12/14/01 Label No. 767720048US

I hereby certify that, on the date indicated above, this paper or fee
was deposited with the U.S. Postal Service & that it was ad-
dressed for delivery to the Assistant Commissioner for Patents,
Washington, DC 20231 by "Express Mail Post Office to Ad-
dressee" service.

Name (Print)

Signature

Customer No.:



07278

PATENT TRADEMARK OFFICE

Docket No: 5986/1F684-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lakshmi A. DEVI and Bryen A. JORDAN

Serial No.: t/b/a (U.S. National Phase of International Application No.

PCT/US00/16559 filed June 15, 2000)

Filed: Concurrently herewith

For: **HETERODIMERIC OPIOID G-PROTEIN COUPLED RECEPTORS**

**MARK-UP OF AMENDED SPECIFICATION AND CLAIMS
OF DECEMBER 14, 2001**

Hon. Commissioner of
Patents and Trademarks
Washington, DC 20231

December 14, 2001

Attn.: Box PCT
DO/EO/US

Sir:

IN THE SPECIFICATION:

CROSS REFERENCE TO RELATED APPLICATIONS

This is the U.S. national phase application based upon International Application No. PCT/US00/16559 filed June 15, 2000, and published in English on December 21, 2000.

This application claims the benefit of priority under 35 U.S.C. § 119 based upon U.S. Provisional Application Serial No. 60/139,528 filed June 16, 1999.

The entire disclosures of the prior applications are incorporated herein by reference.

IN THE CLAIMS:

32. (Amended) A method of treating a disease or disorder selected from the group consisting of chronic pain, drug abuse, schizophrenia, depression, central reward pathway, HIV infection, cardiovascular disease, and hypertension, which method comprises administering a therapeutically effective dose of a compound of claim 24 [or a pharmaceutical composition of claim 29, 30 or 31].

33. (New) A method of treating a disease or disorder selected from the group consisting of chronic pain, drug abuse, schizophrenia, depression, central reward pathway, HIV infection, cardiovascular disease, and hypertension, which method comprises administering a therapeutically effective dose of a pharmaceutical composition of claim 29.

34. (New) A method of treating a disease or disorder selected from the group consisting of chronic pain, drug abuse, schizophrenia, depression, central reward pathway, HIV infection, cardiovascular disease, and hypertension, which method

comprises administering a therapeutically effective dose of a pharmaceutical composition of claim 30.

35. (New) A method of treating a disease or disorder selected from the group consisting of chronic pain, drug abuse, schizophrenia, depression, central reward pathway, HIV infection, cardiovascular disease, and hypertension, which method comprises administering a therapeutically effective dose of a pharmaceutical composition of claim 31.

10018200-012302